Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes

Triphuridet, Natthaya; Vidhyarkorn, Sirachat; Worakitsitisatorn, Akeanong; Sricharunrat, Thaniya; Teerayathanakul, Narongchai; Auewarakul, Chirayu; Chungklay, Naree; Krongthong, Warabhorn; Luengingkasoot, Supapun; Sornsamdang, Gaidganok; Patumanond, Jayanton; Sritipsukho, Paskorn

doi:10.1016/j.lungcan.2018.05.012

Cited by 12 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The baseline lung cancer detection rates ranged from 0.53% to 1.43% with 53.0–85.71% stage I lung cancer. As noted, the studies of heavy smokers reported the lower prevalence of lung cancer and stage 1 lung cancer using the higher baseline cutoff positive criteria were used for solid and PSN, and subsolid nodules were not defined as positive 76,81,82…”

Section: Summary Of Ldct Screening For Lung Cancer Trials In Asiamentioning

confidence: 95%

“…Triphuridet et al80,82 reported a high lung cancer detection rate (1.4%) of a prospective LDCT screening in endemic areas of tuberculosis (TB) started in 2012 among 634 heavy smokers aged 50–70 years without a history of active TB. Baseline lung cancer detection rate was 1.4% with 56% lung cancer being stage I.…”

Section: Ldct Screening For Lung Cancer In Asiamentioning

confidence: 99%

“…There are three prospective studies on annual LDCT screening in smokers from Israel,78 Thailand,81,82 and Korea76 Two studies screened among heavy smoker with the history of tobacco smoking pack at least 30 pack-year aged 50–55 years or older76,81,82 and one study screened among younger and lighter smoker as minimum aged of 40 years with 10 pack-year smoking history 78. The baseline lung cancer detection rates ranged from 0.53% to 1.43% with 53.0–85.71% stage I lung cancer.…”

Section: Summary Of Ldct Screening For Lung Cancer Trials In Asiamentioning

confidence: 99%

See 2 more Smart Citations

<p>Landscape on CT screening for lung cancer in Asia</p>

Triphuridet

Henschke

2019

LCTT

Self Cite

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer incidence and mortality worldwide. Approximately 60% of the world’s new cases of lung cancer and deaths from it are expected in Asia in 2018. Currently, lung cancer screening using low-dose computed tomography (LDCT) is recommended for heavy smokers in North America, Europe and some countries in Asia. Tobacco smoking being the major risk factor for lung cancer, but in Asia, lung cancer in never-smokers (LCINS) is also a concern. This paper reviews on lung cancer incidence, mortality, etiology, smoking in Asia, and systematic reviews on LDCT lung cancer screening studies, including ongoing projects and recommendation on lung cancer screening in Asia. Some of the earliest studies of LDCT lung cancer screening worldwide were in Asia. Many countries in Asia have developed LDCT screening studies in various high-risk participants. Currently, there are several ongoing large-scale lung cancer screening trials to evaluate the efficacy of LDCT screening for never-smokers and light smokers, as well as heavy smokers, and to evaluate the feasibility of population-based LDCT lung cancer screening.

show abstract

Section: Summary Of Ldct Screening For Lung Cancer Trials In Asiamentioning

confidence: 95%

Section: Ldct Screening For Lung Cancer In Asiamentioning

confidence: 99%

Section: Summary Of Ldct Screening For Lung Cancer Trials In Asiamentioning

confidence: 99%

See 1 more Smart Citation

<p>Landscape on CT screening for lung cancer in Asia</p>

Triphuridet

Henschke

2019

LCTT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although numerous studies have evaluated biomarkers as indicators of lung cancer, no screening studies have included them as part of their protocol. Several reports have shown that panels of circulating tumour-related proteins can identify patients with lung cancer [63][64][65][66]. One study that detected auto-antibodies against a panel of six tumour-related antigens found that the panel identified 40% of primary lung cancers (only 33% of stage I), with a specificity of 90% vs. matched controls [66].…”

Section: Biomarkers For the Selection Of Individuals For Ldct-lcsmentioning

confidence: 99%

Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Veronesi

Baldwin

Henschke

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39–61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the “Initiative for European Lung Screening (IELS)”—a large international group of physicians and other experts concerned with lung cancer—agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.

show abstract

“…Currently, low dose computed tomography (LDCT) is a common and accessible tool for lung cancer diagnosis in clinics. However, the shortness of LDCT is that it has a high false positive rate, limiting its e cacy in helping to identify cancer [2]. There is therefore a need to pursue a minimally invasive, convenient, and easy to access method − the serum tumor marker to help the screening, diagnoses, therapeutic monitoring, and prognostication of lung cancer [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

Li¹,

Zhang²,

Jiang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Lung cancer is the most common neoplasm among all cancers worldwide. Early diagnosis with minimal invasive procedures is ideal for lowering the patients’ burden and increasing survival rates. The value of serum tumor biomarkers used in lung cancer screening is still controversial in clinical practice.Methods: Serum levels of ProGRP, NSE, SCC-Ag, CEA, CYFRA21-1, and HE4 were measured using the chemiluminescence immunoassay in apparently healthy Chinese individuals, as well as in those with benign non-cancerous diseases, lung cancer patients, and those suffering other types of malignancies. Data was analyzed utilizing the SPSS version 18.0 statistical software. Results: All 6 serum biomarkers in lung cancers were significantly higher than in benign non-cancerous diseases and healthy controls. HE4 levels in benign diseases were significantly higher than in healthy controls. SCC-Ag, CEA, and CYFRA21-1 levels in lung cancers were significantly higher than in other malignancies. ProGRP and NSE levels in SCLC were significantly higher than in other histologic types; SCC-Ag and CYFRA21-1 levels in SCC were significantly higher than in other histologic types; the HE4 level in SCLC was also significantly higher than in SCC and adenocarcinoma, while adenocarcinoma had the highest serum CEA level comparing to SCC and SCLC. Serum ProGRP, NSE, and HE4 in SCLC were significantly higher than in NSCLC, SCC-Ag level in NSCLC was significantly higher than in SCLC. All biomarkers in advanced stages were significantly higher than in lower stages. NSE, HE4, and ProGRP presented relative high performance in SCLC. CYFRA21-1, HE4, and SCC-Ag indicated relative high performance in SCC. All biomarkers had relatively low performance on adenocarcinoma histologic type. The best performance of 2-marker combination was SCC-Ag+CYFRA21-1 for SCC, ProGRP+NSE for SCLC, CEA+CYFRA21-1 for adenocarcinoma. A combination of SCC+CEA+CYFRA21-1 gained highest performance for NSCLC.Conclusions: A 6-biomarker panel had capability on characterizing lung cancer and presented high performance individually and combinatorically on different histologic types of the neoplasm. HE4 showed high sensitivity to all histologic types of the malignancy; however, one should be cautious since its level also increased in benign non-cancerous diseases.

show abstract

Screening values of carcinoembryonic antigen and cytokeratin 19 fragment for lung cancer in combination with low-dose computed tomography in high-risk populations: Initial and 2-year screening outcomes

Cited by 12 publications

References 20 publications

<p>Landscape on CT screening for lung cancer in Asia</p>

<p>Landscape on CT screening for lung cancer in Asia</p>

Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

Contact Info

Product

Resources

About